David Dally

David Dally joined Engitix as Chief Financial Officer (CFO) in November 2018.

Mr Dally has over 20 years of experience in the biotech and pharmaceutical industry, working in finance and general management across companies of varying size, financial ownership and geographical location, including in the UK, the US and Asia.

Mr Dally is an experienced executive having held the position of CEO at MerLion Pharmaceuticals since 2013, before which he was CFO from 2007. He was also consultant CEO for Reproductive Sciences Ltd from 2016 to 2018.

During his career, Mr Dally has been CFO for several companies including KuDOS Pharmaceuticals (which was sold to AstraZeneca for $210 million), Rhytec Ltd, and Dyson. He established his career as a financial leader through various roles at Amersham plc (now GE Healthcare), latterly as Vice President of finance, North America where he oversaw the merger of Amersham Life Science with Pharmacia Biotech.

David is a chartered accountant and holds a MA in Geography from the University of Cambridge.